Arycs Technologies | $24,000,000 | (Mar 13, 2026)
Ezra(2) | $8,000,000 | (Mar 13, 2026)
Freestyle | $10,000,000 | (Mar 13, 2026)
Certified by Founder
Lodge
Sable Bio
start up
United Kingdom
- London
- 06/02/2024
- Pre-Seed
- $1,883,707
Prevent target safety failures with unique data insights and cutting-edge approaches.
Better prediction of drug safety could help patients and prevent hugely costly trial failures. Our advanced workflows assess clinical side effects and predict potential risks for drugs in development using a suite of data modalities.
Empower your drug development process with our state-of-the-art solutions. Build trust with industry-leading validation across several proof points. Gain deeper insights into target safety, minimize risks, and optimize assay validation strategies.
- Industry Biotechnology Research
- Website https://sablebio.com/
- LinkedIn https://www.linkedin.com/company/sable-bio/
Mantis Space | $10,000,000 | (Mar 13, 2026)
Monteris Medical | $28,000,000 | (Mar 13, 2026)
Gumloop | $50,000,000 | (Mar 13, 2026)
Combat Medical Ltd | $3,472,639 | (Mar 13, 2026)
Qurrent | $15,000,000 | (Mar 13, 2026)
Waiv, formerly Owkin Dx | $33,000,000 | (Mar 13, 2026)
Carefam | $14,500,000 | (Mar 13, 2026)
Option Circle | $3,000,000 | (Mar 12, 2026)